stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Gross margin
NeoGenomics, Inc.'s gross margin over the twelve months to 30 September 2026 was 44.8%, up 1.6 percentage points from fiscal 2025 (43.2%). Over the past ten years it has ranged from 36.9% (fiscal 2022) to 48.2% (fiscal 2019); the current reading is higher than 64% of that period. That is below the Diagnostics & Research industry median of 48.3% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 43.2% | (0.71) |
| FY2024 | 43.9% | 2.58 |
| FY2023 | 41.3% | 4.48 |
| FY2022 | 36.9% | (1.76) |
| FY2021 | 38.6% | (3.21) |
| FY2020 | 41.8% | (6.32) |
| FY2019 | 48.2% | 2.16 |
| FY2018 | 46.0% | 3.55 |
| FY2017 | 42.4% | 0.12 |
| FY2016 | 42.3% | (1.52) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 46.2% | 0.60 |
| Jun 2026 | 45.6% | 2.24 |
| Mar 2026 | 43.3% | (0.51) |
| Dec 2025 | 43.8% | 0.99 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| CSTL Castle Biosciences, Inc. compare | 77.1% |
| ADPT Adaptive Biotechnologies Corporation compare | 74.2% |
| VCYT Veracyte, Inc. compare | 72.0% |
| CDNA CareDx, Inc. compare | 71.0% |
| WGS GeneDx Holdings Corp. compare | 69.4% |
| OPK OPKO Health, Inc. compare | 46.2% |
| NEO NeoGenomics, Inc. | 44.8% |
| PSNL Personalis, Inc. compare | 16.7% |
| FRNM Freenome, Inc compare | — |
| Diagnostics & Research industry median | 48.3% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement